FOLH1 and neoplasm: Lastly, a radiopharmaceutical agent, such as radium‐223 if bone metastases are prominent or a PSMA‐targeted agent if soft tissue metastases are dominant, would continue the cascade of tumour antigen release and with ICB could promote long‐lasting tumour immunity.